Trial Profile
An open-label, single-arm, Phase II study investigating the efficacy of PBI-4050 in patients with type 2 diabetes and multi-organ fibrosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Fezagepras (Primary)
- Indications Fibrosis
- Focus Therapeutic Use
- 21 Jul 2022 According to Liminal BioSciences media release, the company has discontinued development of fezagepras based on results from the Phase 1a single ascending dose ("SAD") clinical trial, which indicated fezagepras was significantly inferior compared to Sodium Phenylbutyrate as a nitrogen scavenger. The recommendation to stop the development program for fezagepras was not based on safety concerns.
- 21 Jul 2022 Status changed from not yet recruiting to discontinued, according to a Liminal BioSciences media release.
- 09 Feb 2016 Preliminary data expected in H2 2016, as per ProMetic media release.